Can the EU Biotech Act Restore Pharmaceutical Competitiveness?

Can the EU Biotech Act Restore Pharmaceutical Competitiveness?

Active pharmaceutical ingredient manufacturing is increasingly viewed through the lens of strategic autonomy as European leaders seek to reduce their heavy reliance on Chinese supply chains. This legislative movement marks a profound shift in how the European Union perceives its industrial security and scientific future at a time when its once-dominant pharmaceutical sector faces an existential crisis of relevance. For decades, the region enjoyed a reputation as the world’s pharmacy, but recent years have shown a persistent migration of high-value innovation to more agile markets in North America and the Asia-Pacific. The proposed European Biotech Act serves as a cornerstone of this new strategy, aiming to modernize a regulatory architecture that has often been criticized for its excessive complexity and slow pace of approval. By streamlining these rules, the EU intends to foster an environment where laboratory breakthroughs can move to the clinical stage with the same speed seen in competing global markets. This initiative is born from the realization that Europe cannot simply rely on its historic prestige while its global market share continues to erode in the face of aggressive international competition and shifting trade dynamics.

Reversing the Decline of Innovation

Addressing the Erosion of Global Competitiveness

The shifting geography of medical research represents a significant challenge for European policymakers who are currently witnessing a steady exodus of clinical trials to more favorable jurisdictions. Current statistics indicate that China’s share of global clinical research has expanded from 8% just eight years ago to a substantial 22% today, effectively tripling its influence in the sector while the European share continues to contract. Industry experts from the Czech Association of the Innovative Pharmaceutical Industry (AIFP) emphasize that this “loss of speed” is not merely a bureaucratic concern but a fundamental threat to the continent’s intellectual capital. If this trend remains unchecked during the period from 2026 to 2028, Europe risks being permanently sidelined as a primary developer of life-saving medicines and becoming a secondary market for technologies developed elsewhere. This decline is further exacerbated by the increasing difficulty of retaining top-tier research talent within the borders of the European Union, as many experts find better resources abroad.

As pharmaceutical companies prioritize investments in regions with faster regulatory pathways and more aggressive fiscal incentives, the infrastructure for high-level clinical research in Europe begins to degrade significantly. The European Federation of Pharmaceutical Industries and Associations (EFPIA) has noted that the lack of a unified and rapid approval process makes it difficult for local hospitals and universities to participate in global multi-center trials. Consequently, European patients may find themselves waiting longer for access to experimental treatments that are readily available in other jurisdictions, creating a disparity in healthcare quality. Reversing this trend requires a fundamental rethink of how the EU promotes itself as a global hub for innovation, ensuring that the regulatory environment acts as a catalyst rather than a barrier to progress in the medical field. Strengthening the connection between academic research and industrial application is essential for maintaining a vibrant scientific community that can respond to the health challenges of the next decade.

Strengthening Intellectual Property Incentives

A central and often debated component of the Biotech Act involves the proposal to extend the Supplementary Protection Certificate (SPC) by a period of 12 months. This extension is intended to act as a financial buffer for companies that spend years navigating the rigorous and often lengthy European regulatory approval process, which effectively consumes their patent life. Proponents of the measure argue that such an extension provides a much-needed signal to global investors that the European market remains a stable and rewarding environment for high-risk biotechnology ventures. Without these robust intellectual property protections, venture capital is likely to continue its flight toward the United States, where market exclusivity periods are often perceived as more favorable and predictable. The logic behind the SPC extension is that by rewarding the high costs of drug discovery, the EU can anchor pharmaceutical research within its territory and prevent the continued loss of valuable industrial assets to international rivals.

However, the debate over intellectual property is not limited to mere financial numbers; it represents a fundamental question of how Europe values innovation in the modern era. Industry leaders argue that the inherent risks of biotechnology—where the vast majority of experimental compounds fail during clinical development—necessitate a legal framework that guarantees a return on investment for successful products. The 12-month extension is seen as a pragmatic compromise that compensates for the administrative delays that are often unique to the European single market’s multi-layered governance system. By providing this additional window of protection, the Biotech Act aims to create a more predictable environment for long-term industrial planning and capital allocation. This predictability is essential for companies deciding where to locate their next generation of laboratory facilities and advanced manufacturing plants. Ultimately, the goal is to ensure that the European Union can compete on equal footing with other global powers that have already optimized their incentive structures.

Balancing Access and Strategic Security

Prioritizing Patient Advocacy and Affordability

While the pharmaceutical industry focuses on commercial incentives, patient advocacy groups like the European Patients’ Forum express significant reservations regarding the extension of market protections. The primary concern is that any delay in the entry of generic and biosimilar medicines directly translates to higher costs for national healthcare systems that are already operating under severe fiscal constraints. Critics of the SPC extension argue that there is no definitive empirical evidence linking longer patent-like protections to improved patient outcomes or even a guaranteed increase in local research investment. From their perspective, the priority of the Biotech Act should be to ensure that the fruits of medical innovation are both affordable and accessible to all citizens regardless of their economic status. This tension highlights the difficulty of creating a legislative framework that satisfies the demands of global capital while upholding the principles of the European social model.

To bridge this gap, some advocates are calling for a “conditionality” model for incentives, where pharmaceutical companies would only receive extended protections if they meet specific public health criteria. This could include a requirement to launch products simultaneously across all member states or to ensure a stable supply of essential medicines during times of market volatility. Such a model seeks to ensure that the public investment in research infrastructure and the legal protections granted by the state yield a clear and measurable benefit to the broader population. By linking incentives to access, policymakers hope to mitigate the risk of widening health inequalities between wealthier and less affluent member states within the Union. The challenge lies in designing these conditions in a way that remains attractive to innovators without becoming so burdensome that they choose to avoid the European market altogether. This dialogue remains a critical part of the ongoing negotiations to ensure the Act achieves broad social legitimacy.

Enhancing Strategic Autonomy and Supply Chains

Beyond the debate over pricing and innovation, the Biotech Act introduces a geopolitical dimension to pharmaceutical policy by emphasizing the need for strategic autonomy. European leaders have become increasingly concerned about the continent’s heavy reliance on external suppliers for active pharmaceutical ingredients and raw materials, particularly those sourced from China. This vulnerability was laid bare during recent global disruptions, where supply chain bottlenecks led to significant shortages of basic medications across several member states. In response, the Act proposes reclassifying the pharmaceutical sector as a strategic industry, placing it on the same level of importance as energy production or defense manufacturing. This shift allows for new forms of state support and cross-border cooperation that were previously restricted by strict competition rules. The objective is to build a resilient domestic production base that can withstand geopolitical shocks and ensure consistent access to life-saving drugs.

Building a more self-sufficient pharmaceutical ecosystem requires a massive coordinated effort to bring manufacturing back to European soil through targeted investments. This involves not only constructing new facilities but also modernizing existing ones to meet the high environmental and safety standards required by current EU law. By incentivizing the domestic production of essential substances, the Biotech Act aims to reduce the risk of coercive trade practices or sudden supply cutoffs that could jeopardize public health. Furthermore, this focus on strategic autonomy aligns with broader efforts to strengthen the European industrial base and create high-skilled jobs in the green and digital sectors. The realization that medicine is a fundamental pillar of national security has fundamentally changed the tone of the pharmaceutical debate, moving it away from a purely economic discussion toward one centered on resilience and regional stability. This transformation is expected to guide European investment priorities as the continent seeks to insulate itself from global volatility.

Harmonizing the European Market

Streamlining Regulatory and Administrative Procedures

One of the most tangible benefits of the Biotech Act is its focus on harmonizing the often-fragmented regulatory landscape across the 27 member states of the European Union. Currently, a pharmaceutical company wishing to conduct a multi-national clinical trial must navigate a labyrinth of different national requirements, administrative procedures, and ethical review timelines. This complexity often leads to significant delays, making Europe a less attractive location for research compared to the more centralized systems found in the United States or China. By centralizing the approval process and creating common standards for trial data, the Act seeks to leverage the true power of the EU single market for the first time. Proponents believe that reducing these “low-hanging” administrative hurdles could provide an immediate boost to the continent’s competitiveness without requiring significant new financial expenditures from the public purse.

Furthermore, the harmonization efforts extend to the digital integration of health data, which is increasingly becoming the backbone of modern medical research and drug development. The lack of interoperability between national health databases has historically prevented European researchers from conducting large-scale real-world evidence studies that are essential for modern medicine. The Biotech Act aims to address this by establishing clear protocols for the secure sharing of anonymized patient data across borders, fostering a collaborative research environment that spans the entire continent. Such integration would not only speed up the identification of potential trial participants but also allow for more accurate monitoring of drug safety and efficacy once products are on the market. By transforming the EU into a single, cohesive health data space, the legislation seeks to provide a unique advantage that few other regions can match. This effort to modernize the administrative and digital infrastructure is viewed as a critical step in restoring leadership.

Adopting a Holistic Lifecycle Approach

Success in the modern biotechnology sector requires a comprehensive strategy that views the pharmaceutical lifecycle as an interconnected chain rather than a series of isolated steps. Policymakers recognize that accelerating the approval of new drugs is of limited value if the rest of the ecosystem—from basic laboratory research to large-scale manufacturing and patient reimbursement—is not equally efficient. The Biotech Act encourages a holistic approach that seeks to synchronize these various stages, ensuring that a breakthrough in a university lab can effectively be scaled into a mass-produced treatment. This requires not only legislative changes but also significant investment in the physical and human infrastructure of the healthcare sector across all member states. For instance, speeding up trial approvals will have little impact if national health systems lack the specialized staff or modern facilities required to conduct complex gene therapies or personalized medicine trials.

This lifecycle perspective also highlights the importance of the final stages of the process, particularly the pricing and reimbursement negotiations that occur at the national level. Even the most innovative medicine provides no value if it remains stuck in a lengthy negotiation process between manufacturers and national health ministries. The Biotech Act seeks to encourage more transparent and collaborative dialogue between these stakeholders early in the development process, allowing for a more predictable path to market access. By fostering a more integrated relationship between innovators and payers, the EU hopes to reduce the time it takes for new treatments to reach the patients who need them most. This focus on the entire value chain reflects a shift away from piecemeal reform toward a more coordinated industrial policy. Ensuring that every link in the chain—from the initial spark of an idea to the delivery of a treatment—is strong and efficient is regarded as essential for maintaining the long-term viability of the sector.

Integrating Modern Technology and Global Governance

The rapid advancement of artificial intelligence and machine learning is fundamentally changing the landscape of drug discovery, and the Biotech Act must find a way to integrate these technologies into its framework. Some stakeholders argue that if AI can significantly reduce the time and cost associated with identifying new drug candidates, the traditional justifications for extended patent protections may need to be reevaluated. In this view, the efficiency gains provided by technology could offset the high risks that have historically justified long periods of market exclusivity. However, industry representatives maintain that while AI is a powerful tool for optimization, the inherent biological complexities and the rigorous requirements of clinical trials remain unchanged. They argue that the massive financial investments required to move a digital discovery into a physical, life-saving treatment still necessitate robust intellectual property rights to sustain the research ecosystem over the long term.

Establishing a governance model that balanced the potential of advanced technology with the need for transparency and human oversight was regarded as essential for maintaining public trust. To ensure the Biotech Act delivers on its promises, the European Commission recommended that member states prioritize the development of digital sandboxes where AI-driven drug discovery could be tested under supervised conditions. This forward-looking approach allowed the Union to refine its regulatory requirements in real-time as the technology matured. Additionally, the integration of patient representatives into the decision-making process for strategic projects ensured that research priorities remained aligned with actual medical needs. By fostering an environment of inclusive governance and technological agility, the EU sought to create a “third way” that combined high-tech innovation with social responsibility. The success of these initiatives required a sustained commitment to funding digital infrastructure and a willingness to adapt regulatory frameworks to the realities of a data-driven global economy.

Subscribe to our weekly news digest

Keep up to date with the latest news and events

Paperplanes Paperplanes Paperplanes
Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later